<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
 <result pre="a prophylactic is doubtful. An effective prophylactic medication to prevent" exact="viral" post="entry has to contain, at least, either a protease"/>
 <result pre="that selectively inhibits TMPRSS2 and, in so doing, inhibits TMPRSS2-specific" exact="viral" post="entry is likely to be effective against SARS-CoV-2. We"/>
 <result pre="to the WHO, as of April 18, 2020, coronavirus (CoV)" exact="disease" post="2019 (COVID-19) has caused more than 2,000,000 confirmed cases"/>
 <result pre="world witnesses the alarming levels of spread and severity of" exact="atypical pneumonia" post="COVID-19, strategies to combat this outbreak are in dire"/>
 <result pre="witnesses the alarming levels of spread and severity of atypical" exact="pneumonia" post="COVID-19, strategies to combat this outbreak are in dire"/>
 <result pre="in recent memory. These include SARS, MERS, the Zika virus," exact="swine flu," post="and Ebola. This is the third documented coronavirus (CoV)"/>
 <result pre="to humans (zoonosis) in 2 decades. Previous outbreaks were severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) [3, 4] and Middle-East respiratory"/>
 <result pre="humans (zoonosis) in 2 decades. Previous outbreaks were severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) [3, 4] and Middle-East respiratory syndrome"/>
 <result pre="(zoonosis) in 2 decades. Previous outbreaks were severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) [3, 4] and Middle-East respiratory syndrome coronavirus"/>
 <result pre="severe acute respiratory syndrome coronavirus (SARS-CoV) [3, 4] and Middle-East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) [5]. We are now dealing with"/>
 <result pre="acute respiratory syndrome coronavirus (SARS-CoV) [3, 4] and Middle-East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) [5]. We are now dealing with the"/>
 <result pre="We are now dealing with the novel CoV causing severe" exact="acute" post="respiratory syndrome (SARS), originally termed 2019-nCoV, and now designated"/>
 <result pre="are now dealing with the novel CoV causing severe acute" exact="respiratory" post="syndrome (SARS), originally termed 2019-nCoV, and now designated SARS-CoV-2"/>
 <result pre="now dealing with the novel CoV causing severe acute respiratory" exact="syndrome" post="(SARS), originally termed 2019-nCoV, and now designated SARS-CoV-2 [6,"/>
 <result pre="putative, functional open-reading frames (ORFs) responsible for the synthesis of" exact="viral" post="structural and nonstructural proteins [9, 10]. The genome encodes"/>
 <result pre="domain (TM), and cytoplasmic domain (CP), responsible for fusion of" exact="viral" post="and cellular membranes [10] (Fig.Â 2). The S2 subunit"/>
 <result pre="[10] (Fig.Â 2). The S2 subunit mediates subsequent fusion between" exact="viral" post="and host cellular membranes, facilitating entry into the host"/>
 <result pre="explain why COVID-19 appears to spread more easily, mainly by" exact="respiratory" post="transmission, from person to person. Fig. 2 SARS-CoV-2 S"/>
 <result pre="transmission, from person to person. Fig. 2 SARS-CoV-2 S protein" exact="primary" post="structure. The S protein consists of two subunits: The"/>
 <result pre="domain (TM), and cytoplasmic domain (CP), responsible for fusion of" exact="viral" post="and cellular membranes [10] An important question is why"/>
 <result pre="One possible reason could be due to the large alveolar" exact="epithelial" post="surface of the lungs being incredibly susceptible to inhaled"/>
 <result pre="and colleagues describe that approximately 85% of ACE2-expressing cells are" exact="epithelial" post="type II alveolar cells (AECII, or AT2). This particularly"/>
 <result pre="colleagues describe that approximately 85% of ACE2-expressing cells are epithelial" exact="type II" post="alveolar cells (AECII, or AT2). This particularly suggests that"/>
 <result pre="This particularly suggests that these cells are a preference for" exact="viral" post="invasion. In addition, genetic analysis indicates that ACE2-expressing AECII"/>
 <result pre="high level of multiple proviral genes, including regulatory genes for" exact="viral" post="processes, viral life cycle, viral reproduction, and genome replication"/>
 <result pre="of multiple proviral genes, including regulatory genes for viral processes," exact="viral" post="life cycle, viral reproduction, and genome replication [16]. This"/>
 <result pre="genes, including regulatory genes for viral processes, viral life cycle," exact="viral" post="reproduction, and genome replication [16]. This infers that ACE2-expressing"/>
 <result pre="CoVs in the lungs and are, therefore, essentially responsible for" exact="pulmonary" post="complications. The expression of the ACE2 receptor was also"/>
 <result pre="kidney, endothelium, and intestine [17, 18]. Theoretically, there could be" exact="viral" post="invasion and replication in any of these tissues. However,"/>
 <result pre="all of the fulminant trends of the virus are primarily" exact="pulmonary" post="[16]. This organ seems to be the main replication"/>
 <result pre="should, therefore, first target the lungs to prevent a generalized" exact="infection" post="or at least mitigate the symptoms. ACE2 is also"/>
 <result pre="strongly expressed and used on the lumen surface of intestinal" exact="epithelial" post="cells as a co-receptor for the absorption of nutrients,"/>
 <result pre="an important entry point for SARS-CoV-2 and that the first" exact="infection" post="with SARS-CoV-2 may have resulted from eating food from"/>
 <result pre="strategies for COVID-19 The topic of clinical management of SARS-CoV-2" exact="infections" post="is too vast to be adequately covered in the"/>
 <result pre="considerations important to frontline clinical personnel. Although patients with COVID-19" exact="pneumonia" post="and respiratory distress share many clinical similarities with patients"/>
 <result pre="to frontline clinical personnel. Although patients with COVID-19 pneumonia and" exact="respiratory" post="distress share many clinical similarities with patients suffering from"/>
 <result pre="clinical similarities with patients suffering from other types of severe" exact="viral pneumonia" post="and often meet the Berlin definition of acute respiratory"/>
 <result pre="similarities with patients suffering from other types of severe viral" exact="pneumonia" post="and often meet the Berlin definition of acute respiratory"/>
 <result pre="severe viral pneumonia and often meet the Berlin definition of" exact="acute" post="respiratory distress syndrome (ARDS) [21], accumulating clinical evidence suggests"/>
 <result pre="viral pneumonia and often meet the Berlin definition of acute" exact="respiratory" post="distress syndrome (ARDS) [21], accumulating clinical evidence suggests that"/>
 <result pre="and often meet the Berlin definition of acute respiratory distress" exact="syndrome" post="(ARDS) [21], accumulating clinical evidence suggests that there are"/>
 <result pre="department (ED) arrival, patients can decompensate quickly depending upon their" exact="viral" post="load, comorbidities, and length of clinical illness among other"/>
 <result pre="illness among other factors. A systematic, escalating, step-wise approach to" exact="respiratory" post="support is essential. A patient who arrives to the"/>
 <result pre="is essential. A patient who arrives to the ED with" exact="hypoxia" post="should immediately be placed on nasal cannula (NC) or"/>
 <result pre="and their response monitored closely. Currently, the treatment is mainly" exact="symptomatic" post="and supportive care, and for patients with severe infection"/>
 <result pre="mainly symptomatic and supportive care, and for patients with severe" exact="infection" post="oxygen therapy represents the major treatment intervention. Preventive strategies"/>
 <result pre="transmission are focused on the isolation of patients and careful" exact="infection" post="control. Vaccine development against SARS-CoV-2 is in advanced stages"/>
 <result pre="virus families and have already been used for treating other" exact="viral" post="infections in a clinical setting, indicating potential broad-spectrum applications."/>
 <result pre="families and have already been used for treating other viral" exact="infections" post="in a clinical setting, indicating potential broad-spectrum applications. Interference"/>
 <result pre="in a clinical setting, indicating potential broad-spectrum applications. Interference with" exact="viral" post="host cell entry An S protein-based antiviral As the"/>
 <result pre="cells, it is the main target of neutralizing antibodies upon" exact="infection" post="and the focus of therapeutic and vaccine design. The"/>
 <result pre="fusion of the virus with the ACE2 receptor needed for" exact="viral" post="entry and spread of SARS-CoV-2 [25]. Hoffmann et al."/>
 <result pre="antiviral intervention. TMPRSS2 plays a crucial role in modulating the" exact="metastatic" post="behavior of certain tumors, e.g., in prostate cancer and"/>
 <result pre="in modulating the metastatic behavior of certain tumors, e.g., in" exact="prostate cancer" post="and in modulating inflammation of organs, such as in"/>
 <result pre="modulating the metastatic behavior of certain tumors, e.g., in prostate" exact="cancer" post="and in modulating inflammation of organs, such as in"/>
 <result pre="TMPRSS2 inhibitor. It is currently only approved for treatment of" exact="chronic" post="pancreatitis in Japan [27]. Very little data are available"/>
 <result pre="inhibitor. It is currently only approved for treatment of chronic" exact="pancreatitis" post="in Japan [27]. Very little data are available on"/>
 <result pre="currently undergoing Phase 1/2 trial testing in the USA for" exact="chronic" post="pancreatitis [28]. If deemed safe, it could be a"/>
 <result pre="undergoing Phase 1/2 trial testing in the USA for chronic" exact="pancreatitis" post="[28]. If deemed safe, it could be a potential"/>
 <result pre="safe, it could be a potential treatment option of CoV" exact="infections" post="[29]. Nafamostat mesilate is also a serine protease inhibitor"/>
 <result pre="used as an anticoagulant and used to treat pancreatic and" exact="kidney disease." post="It is structurally closely related to camostat mesilate. Researchers"/>
 <result pre="be considered in non-emergency care. TMPRSS2 is expressed highly in" exact="localized" post="high-grade prostate cancers and in the majority of human"/>
 <result pre="localized high-grade prostate cancers and in the majority of human" exact="prostate cancer" post="metastases. Lucas et al. [31] showed a decrease in"/>
 <result pre="high-grade prostate cancers and in the majority of human prostate" exact="cancer" post="metastases. Lucas et al. [31] showed a decrease in"/>
 <result pre="a slowdown of the spread of metastases in mice with" exact="prostate cancer" post="using TMPRSS2 inhibitors. In particular, they identified bromhexine, an"/>
 <result pre="slowdown of the spread of metastases in mice with prostate" exact="cancer" post="using TMPRSS2 inhibitors. In particular, they identified bromhexine, an"/>
 <result pre="severity of COVID-19. Commercially available antiandrogens include, but are not" exact="limited" post="to bicalutamide, enzalutamide, apalutamide, flutamide, nilutamide, or darolutamide [35]."/>
 <result pre="bicalutamide, enzalutamide, apalutamide, flutamide, nilutamide, or darolutamide [35]. Interference with" exact="viral" post="fusion and uptake Viral fusion and release of the"/>
 <result pre="nilutamide, or darolutamide [35]. Interference with viral fusion and uptake" exact="Viral" post="fusion and release of the genetic components are highly"/>
 <result pre="(N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine), an FDA-approved drug, [36] has been used to treat" exact="malaria" post="for many years, [37] as well as autoimmune diseases."/>
 <result pre="to treat malaria for many years, [37] as well as" exact="autoimmune diseases." post="Chloroquine is known to block virus infection by increasing"/>
 <result pre="as well as autoimmune diseases. Chloroquine is known to block" exact="virus infection" post="by increasing endosomal pH required for virus/endosome fusion [38]"/>
 <result pre="well as autoimmune diseases. Chloroquine is known to block virus" exact="infection" post="by increasing endosomal pH required for virus/endosome fusion [38]"/>
 <result pre="endosomal pH required for virus/endosome fusion [38] and release of" exact="viral" post="DNA or RNA into the cytosol. Moreover, chloroquine has"/>
 <result pre="a novel class of autophagy inhibitor, [40] further interfering with" exact="viral infection" post="and replication. A combination of remdesivir and chloroquine was"/>
 <result pre="novel class of autophagy inhibitor, [40] further interfering with viral" exact="infection" post="and replication. A combination of remdesivir and chloroquine was"/>
 <result pre="applicable against COVID-19. However, an overdose of chloroquine can cause" exact="acute" post="poisoning and death [43]. HCQ sulfate, a derivative of"/>
 <result pre="an imperative lung protective function [45] and is, therefore, of" exact="limited" post="use as a target as it has to maintain"/>
 <result pre="maintain its physiological function. ACE2 inhibitors will go hand-in-hand with" exact="partial" post="loss of this lung protection. Chloroquine and the less"/>
 <result pre="adjuvant to prevent or to weaken the course of such" exact="viral" post="infections. Cathepsin B/L activity is inhibited by an elevated"/>
 <result pre="and, thus, chloroquine treatment will also work [52]. Interference with" exact="viral" post="replication Interference with RNA-dependent RNA polymerase Remdesivir (GS-5734) is"/>
 <result pre="reduction in the replication of the virus and of the" exact="total" post="initial viral load in the host cells, especially in"/>
 <result pre="the replication of the virus and of the total initial" exact="viral" post="load in the host cells, especially in young and"/>
 <result pre="acts as a mucolytic (breaks down mucus and helps clear" exact="chest" post="congestion) and is approved in many countries as an"/>
 <result pre="protective properties have been discussed in infants and severely ill" exact="adult" post="patients as well as the potential as an adjuvant"/>
 <result pre="per dose for adults). It shows a quick and almost" exact="complete" post="absorption in the intestine. Lung-tissue concentrations 2Â h post"/>
 <result pre="bronchiolo-bronchial tissues and between 2.4 and 5.9 times higher in" exact="pulmonary" post="parenchyma compared to plasma concentrations. Unchanged bromhexine is bound"/>
 <result pre="a slowdown of the spread of metastases in mice with" exact="prostate cancer" post="using TMPRSS2 inhibitors. The extent of metastasis reduction with"/>
 <result pre="slowdown of the spread of metastases in mice with prostate" exact="cancer" post="using TMPRSS2 inhibitors. The extent of metastasis reduction with"/>
 <result pre="mice with prostate cancer using TMPRSS2 inhibitors. The extent of" exact="metastasis" post="reduction with bromhexine was slightly lower in the wild-type"/>
 <result pre="inhibitors. The extent of metastasis reduction with bromhexine was slightly" exact="lower" post="in the wild-type mice than in the genetic TMPRSS2âˆ’"/>
 <result pre="genetic TMPRSS2âˆ’ mice. This is most likely due to an" exact="incomplete" post="pharmacological blockage of the protease activity by the applied"/>
 <result pre="and 4Â days on average for the control group), had" exact="lower" post="proportion of patients requiring oxygen inhalation (16.67% for the"/>
 <result pre="the control group), and had smaller incidence of adverse events" exact="of liver" post="injury which is expected (25% for the experimental group"/>
 <result pre="models [70]. Chloroquine in almost all animal models of different" exact="viral" post="infections only partially worked or did not work [71â€&quot;73]."/>
 <result pre="[70]. Chloroquine in almost all animal models of different viral" exact="infections" post="only partially worked or did not work [71â€&quot;73]. Treatment"/>
 <result pre="not work [71â€&quot;73]. Treatment with chloroquine did not prevent influenza" exact="infection" post="in a randomized, double-blind, placebo-controlled clinical trial [74]. Conversely,"/>
 <result pre="the discussed glycosylation of the binding pocket [38]. After the" exact="viral infection" post="has spread in the body and due to the"/>
 <result pre="discussed glycosylation of the binding pocket [38]. After the viral" exact="infection" post="has spread in the body and due to the"/>
 <result pre="spread in the body and due to the incredibly high" exact="viral" post="loads, the non-specific endocytotic pathway is mainly used for"/>
 <result pre="combine HCQ with a TMPRSS2 inhibitor, like bromhexine, to block" exact="complete" post="entry of the virus into host cells. In the"/>
 <result pre="endosomal entry is negligible. An effective prophylactic medication to prevent" exact="viral" post="entry has to contain, at least, either a TMPRSS2"/>
 <result pre="virus entry (via HCQ sulfate and quercetin) as well as" exact="viral" post="replication (quercetin). The recommended dose of HCQ sulfate for"/>
 <result pre="derivatives are quite toxic, a combination with bromhexine and a" exact="lower" post="dose of HCQ could be applicable. A combination of"/>
 <result pre="is able to suppress influenza virus replication in human airway" exact="epithelial" post="cells at remarkably lower concentrations compared to a treatment"/>
 <result pre="influenza virus replication in human airway epithelial cells at remarkably" exact="lower" post="concentrations compared to a treatment with each inhibitor alone"/>
 <result pre="supplements like quercetin to contribute to an inhibition of the" exact="viral" post="entry and replication must also be considered as additional"/>
 <result pre="can be activated by TMPRSS2, resulting in fusion of the" exact="viral" post="membrane with the plasma membrane. Activation of the S"/>
 <result pre="by TMPRSS2 can be blocked by bromhexine. Quercetin also blocks" exact="viral" post="replication via inhibition of the viral cysteine protease 3CLpro."/>
 <result pre="bromhexine. Quercetin also blocks viral replication via inhibition of the" exact="viral" post="cysteine protease 3CLpro. ( Adapted from Simmons et al."/>
 <result pre="in the early stages of the outbreak and we have" exact="limited" post="knowledge about the transmission and mutation rate of this"/>
 <result pre="virulent and difficult to eradicate. As specific functions of the" exact="viral" post="proteins and the pathogenicity of the virus become clearer"/>
 <result pre="prophylactic option to prevent or potent drug to treat the" exact="disease" post="progression in these urgent times is the repurposing of"/>
 <result pre="possibly replace HCQ. Second, this combination can be used to" exact="lower" post="the viral burden in newly infected individuals, limiting their"/>
 <result pre="HCQ. Second, this combination can be used to lower the" exact="viral" post="burden in newly infected individuals, limiting their capacity to"/>
 <result pre="entitled â€œEvaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets" exact="Combined" post="with Standard Treatment/ Standard Treatment in Patients with Suspected"/>
 <result pre="Standard Treatment in Patients with Suspected and Mild Novel Coronavirus" exact="Pneumonia" post="(COVID-19)â€�, officially released on Clinical Trials, with a registration"/>
 <result pre="availability Not applicable. References References 1.World Health Organization (2020) Coronavirus" exact="disease" post="(COVID-2019) press briefings. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/media-resources/press-briefings. Accessed 22 Mar 2020 2.World"/>
 <result pre="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/media-resources/press-briefings. Accessed 22 Mar 2020 2.World Health Organization (2020) Coronavirus" exact="Disease" post="(COVID-2019) Situation Reports 1â€&quot;89. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed 18 Apr 2020"/>
 <result pre="WerfSBrodtHRBeckerSet al.Identification of a novel coronavirus in patients with severe" exact="acute" post="respiratory syndromeN Engl J Med2003348201967197610.1056/NEJMoa03074712690091 4.KsiazekTGErdmanDGoldsmithCSZakiSRPeretTEmerySet al.A novel coronavirus"/>
 <result pre="al.Identification of a novel coronavirus in patients with severe acute" exact="respiratory" post="syndromeN Engl J Med2003348201967197610.1056/NEJMoa03074712690091 4.KsiazekTGErdmanDGoldsmithCSZakiSRPeretTEmerySet al.A novel coronavirus associated"/>
 <result pre="Engl J Med2003348201967197610.1056/NEJMoa03074712690091 4.KsiazekTGErdmanDGoldsmithCSZakiSRPeretTEmerySet al.A novel coronavirus associated with severe" exact="acute" post="respiratory syndromeN Engl J Med2003348201953196610.1056/NEJMoa03078112690092 5.ZakiAMvan BoheemenSBestebroerTMOsterhausADFouchierRAIsolation of a"/>
 <result pre="J Med2003348201967197610.1056/NEJMoa03074712690091 4.KsiazekTGErdmanDGoldsmithCSZakiSRPeretTEmerySet al.A novel coronavirus associated with severe acute" exact="respiratory" post="syndromeN Engl J Med2003348201953196610.1056/NEJMoa03078112690092 5.ZakiAMvan BoheemenSBestebroerTMOsterhausADFouchierRAIsolation of a novel"/>
 <result pre="5.ZakiAMvan BoheemenSBestebroerTMOsterhausADFouchierRAIsolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi ArabiaN Engl J Med2012367191814182010.1056/NEJMoa121172123075143 6.GorbalenyaAEBakerSCBaricRSde GrootRJDrostenCGulyaevaAAet al.The"/>
 <result pre="Saudi ArabiaN Engl J Med2012367191814182010.1056/NEJMoa121172123075143 6.GorbalenyaAEBakerSCBaricRSde GrootRJDrostenCGulyaevaAAet al.The species severe" exact="acute" post="respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2Nat"/>
 <result pre="ArabiaN Engl J Med2012367191814182010.1056/NEJMoa121172123075143 6.GorbalenyaAEBakerSCBaricRSde GrootRJDrostenCGulyaevaAAet al.The species severe acute" exact="respiratory" post="syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2Nat Microbiol202010.1038/s41564-020-0695-z"/>
 <result pre="it SARS-CoV-2Nat Microbiol202010.1038/s41564-020-0695-z 7.ZhuNZhangDWangWLiXYangBSongJet al.A Novel Coronavirus from patients with" exact="pneumonia" post="in China, 2019N Engl J Med2020382872773310.1056/NEJMoa200101731978945 8.CascellaMRajnikMCuomoADulebohnSCDi NapoliRFeatures, evaluation"/>
 <result pre="(COVID-19)2020St. PetersburgStatPearls Publishing 9.WuFZhaoSYuBChenYMWangWSongZGet al.A new coronavirus associated with human" exact="respiratory" post="disease in ChinaNature2020579779826526910.1038/s41586-020-2008-332015508 10.ChanJFKokKHZhuZChuHToKKYuanSet al.Genomic characterization of the 2019"/>
 <result pre="PetersburgStatPearls Publishing 9.WuFZhaoSYuBChenYMWangWSongZGet al.A new coronavirus associated with human respiratory" exact="disease" post="in ChinaNature2020579779826526910.1038/s41586-020-2008-332015508 10.ChanJFKokKHZhuZChuHToKKYuanSet al.Genomic characterization of the 2019 novel"/>
 <result pre="the 2019 novel human-pathogenic coronavirus isolated from a patient with" exact="atypical pneumonia" post="after visiting WuhanEmerg Microbes Infect20209122123610.1080/22221751.2020.171990231987001 11.LiGDe ClercqETherapeutic options for"/>
 <result pre="2019 novel human-pathogenic coronavirus isolated from a patient with atypical" exact="pneumonia" post="after visiting WuhanEmerg Microbes Infect20209122123610.1080/22221751.2020.171990231987001 11.LiGDe ClercqETherapeutic options for"/>
 <result pre="2019-nCovBioRxiv202010.1101/2020.01.26.919985 17.CrackowerMASaraoROuditGYYagilCKozieradzkiIScangaSEet al.Angiotensin-converting enzyme 2 is an essential regulator of" exact="heart" post="functionNature2002417689182282810.1038/nature0078612075344 18.GuJGongEZhangBZhengJGaoZZhongYet al.Multiple organ infection and the pathogenesis of"/>
 <result pre="is an essential regulator of heart functionNature2002417689182282810.1038/nature0078612075344 18.GuJGongEZhangBZhengJGaoZZhongYet al.Multiple organ" exact="infection" post="and the pathogenesis of SARSJ Exp Med2005202341542410.1084/jem.2005082816043521 19.HashimotoTPerlotTRehmanATrichereauJIshiguroHPaolinoMet al.ACE2"/>
 <result pre="pathogenesis of SARSJ Exp Med2005202341542410.1084/jem.2005082816043521 19.HashimotoTPerlotTRehmanATrichereauJIshiguroHPaolinoMet al.ACE2 links amino acid" exact="malnutrition" post="to microbial ecology and intestinal inflammationNature2012487740847748110.1038/nature1122822837003 20.YeoCKaushalSYeoDEnteric involvement of"/>
 <result pre="is faecalâ€&quot;oral transmission of SARS-CoV-2 possible?Lancet Gastroenterol Hepatol20205433533710.1016/S2468-1253(20)30048-032087098 21.RanieriVMRubenfeldGDThompsonBTFergusonNDCaldwellEFanEet al.Acute" exact="respiratory" post="distress syndrome: the Berlin DefinitionJAMA2012307232526253310.1001/jama.2012.566922797452 22.GattinoniLChiumelloDCaironiPBusanaMRomittiFBrazziLet al.COVID-19 pneumonia: different"/>
 <result pre="respiratory distress syndrome: the Berlin DefinitionJAMA2012307232526253310.1001/jama.2012.566922797452 22.GattinoniLChiumelloDCaironiPBusanaMRomittiFBrazziLet al.COVID-19 pneumonia: different" exact="respiratory" post="treatment for different phenotypes?Intensive Care Med202010.1007/s00134-020-06033-232291463 23.Craven J (2020)"/>
 <result pre="researchAntiviral Res2013100360561410.1016/j.antiviral.2013.09.02824121034 25.BelouzardSMilletJKLicitraBNWhittakerGRMechanisms of coronavirus cell entry mediated by the" exact="viral" post="spike proteinViruses2012461011103310.3390/v406101122816037 26.HoffmannMKleine-WeberHSchroederSKrugerNHerrlerTErichsenSet al.SARS-CoV-2 cell entry depends on ACE2"/>
 <result pre="the pharmacokinetics, safety, and efficacy of NI-03 in patients with" exact="chronic" post="pancreatitis: study protocol for a randomized controlled trial on"/>
 <result pre="randomized controlled trial on the assessment of camostat treatment in" exact="chronic" post="pancreatitis (TACTIC)Trials201920150110.1186/s13063-019-3606-y31412955 29.ZhouYVedanthamPLuKAgudeloJCarrionRNunneleyJWet al.Protease inhibitors targeting coronavirus and filovirus"/>
 <result pre="controlled trial on the assessment of camostat treatment in chronic" exact="pancreatitis" post="(TACTIC)Trials201920150110.1186/s13063-019-3606-y31412955 29.ZhouYVedanthamPLuKAgudeloJCarrionRNunneleyJWet al.Protease inhibitors targeting coronavirus and filovirus entryAntiviral"/>
 <result pre="al.Identification of nafamostat as a potent inhibitor of middle east" exact="respiratory" post="syndrome coronavirus S protein-mediated membrane fusion using the split-protein-based"/>
 <result pre="of nafamostat as a potent inhibitor of middle east respiratory" exact="syndrome" post="coronavirus S protein-mediated membrane fusion using the split-protein-based cell-cell"/>
 <result pre="protease TMPRSS2 activates a proteolytic cascade involving components of the" exact="tumor" post="microenvironment and promotes prostate cancer metastasisCancer Discov20144111310132510.1158/2159-8290.cd-13-101025122198 32.ChangCCChengACChangABOver-the-counter (OTC)"/>
 <result pre="proteolytic cascade involving components of the tumor microenvironment and promotes" exact="prostate cancer" post="metastasisCancer Discov20144111310132510.1158/2159-8290.cd-13-101025122198 32.ChangCCChengACChangABOver-the-counter (OTC) medications to reduce cough as"/>
 <result pre="cascade involving components of the tumor microenvironment and promotes prostate" exact="cancer" post="metastasisCancer Discov20144111310132510.1158/2159-8290.cd-13-101025122198 32.ChangCCChengACChangABOver-the-counter (OTC) medications to reduce cough as"/>
 <result pre="medications to reduce cough as an adjunct to antibiotics for" exact="acute" post="pneumonia in children and adultsCochrane Database Syst Rev20074Cd00608810.1002/14651858.CD006088.pub2 33.DaneliusEAnderssonHJarvollPLoodKGrÃ¤fensteinJErdÃ©lyiMHalogen"/>
 <result pre="to reduce cough as an adjunct to antibiotics for acute" exact="pneumonia" post="in children and adultsCochrane Database Syst Rev20074Cd00608810.1002/14651858.CD006088.pub2 33.DaneliusEAnderssonHJarvollPLoodKGrÃ¤fensteinJErdÃ©lyiMHalogen bonding:"/>
 <result pre="Resist20188345946410.1016/j.ijpddr.2018.10.00230396013 38.VincentMJBergeronEBenjannetSEricksonBRRollinPEKsiazekTGet al.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol J2005216910.1186/1743-422X-2-6916115318 39.JangCHChoiJHByunMSJueDMChloroquine inhibits production of TNF-alpha, IL-1beta"/>
 <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitroCell Discov2020611610.1038/s41421-020-0156-032194981 47.KubaKImaiYRaoSGaoHGuoFGuanBet al.A crucial role of angiotensin"/>
 <result pre="physiological role in the kidneyMol Cell Biol20032393247325210.1128/MCB.23.9.3247-3252.200312697824 49.DingNZhaoKLanYLiZLvXSuJet al.Induction of" exact="atypical" post="autophagy by porcine hemagglutinating encephalomyelitis virus contributes to viral"/>
 <result pre="Cell Biol20032393247325210.1128/MCB.23.9.3247-3252.200312697824 49.DingNZhaoKLanYLiZLvXSuJet al.Induction of atypical autophagy by porcine hemagglutinating" exact="encephalomyelitis" post="virus contributes to viral replicationFront Cell Infect Microbiol201775610.3389/fcimb.2017.0005628293544 50.TurkVStokaVVasiljevaORenkoMSunTTurkBet"/>
 <result pre="of atypical autophagy by porcine hemagglutinating encephalomyelitis virus contributes to" exact="viral" post="replicationFront Cell Infect Microbiol201775610.3389/fcimb.2017.0005628293544 50.TurkVStokaVVasiljevaORenkoMSunTTurkBet al.Cysteine cathepsins: from structure,"/>
 <result pre="hydroxychloroquine and chloroquine: implications for rheumatologyNat Rev Rheumatol202016315516610.1038/s41584-020-0372-x32034323 53.AgostiniMLAndresELSimsACGrahamRLSheahanTPLuXet al.Coronavirus" exact="susceptibility to" post="the antiviral remdesivir (GS-5734) is mediated by the viral"/>
 <result pre="susceptibility to the antiviral remdesivir (GS-5734) is mediated by the" exact="viral" post="polymerase and the proofreading exoribonucleasemBio201892e00221e31810.1128/mBio.00221-1829511076 54.HolshueMLDeBoltCLindquistSLofyKHWiesmanJBruceHet al.First case of"/>
 <result pre="and pathogenesisMethods Mol Biol (Clifton, NJ)2015128212310.1007/978-1-4939-2438-7_1 56.HarcourtBHJuknelieneDKanjanahaluethaiABechillJSeversonKMSmithCMet al.Identification of severe" exact="acute" post="respiratory syndrome coronavirus replicase products and characterization of papain-like"/>
 <result pre="pathogenesisMethods Mol Biol (Clifton, NJ)2015128212310.1007/978-1-4939-2438-7_1 56.HarcourtBHJuknelieneDKanjanahaluethaiABechillJSeversonKMSmithCMet al.Identification of severe acute" exact="respiratory" post="syndrome coronavirus replicase products and characterization of papain-like protease"/>
 <result pre="Mol Biol (Clifton, NJ)2015128212310.1007/978-1-4939-2438-7_1 56.HarcourtBHJuknelieneDKanjanahaluethaiABechillJSeversonKMSmithCMet al.Identification of severe acute respiratory" exact="syndrome" post="coronavirus replicase products and characterization of papain-like protease activityJ"/>
 <result pre="of the index patient who caused tertiary transmission of COVID-19" exact="infection" post="in Korea: the application of lopinavir/ritonavir for the treatment"/>
 <result pre="the application of lopinavir/ritonavir for the treatment of COVID-19 infected" exact="pneumonia" post="monitored by quantitative RT-PCRJ Korean Med Sci2020356e7910.3346/jkms.2020.35.e7932056407 60.CaoBWangYWenDLiuWWangJFanGet al.A"/>
 <result pre="possibly inhibiting SARS-CoV-2â€™s main proteaseJ Phys Chem Lett2020114413442010.1021/acs.jpclett.0c00994 62.GulatiKRaiNChaudharySRayANutraceuticals in" exact="respiratory" post="disorders2016CambridgeAcademic Press7586 63.HanSMallampalliRKThe role of surfactant in lung disease"/>
 <result pre="62.GulatiKRaiNChaudharySRayANutraceuticals in respiratory disorders2016CambridgeAcademic Press7586 63.HanSMallampalliRKThe role of surfactant in" exact="lung disease" post="and host defense against pulmonary infectionsAnn Am Thorac Soc201512576577410.1513/AnnalsATS.201411-507FR25742123"/>
 <result pre="in respiratory disorders2016CambridgeAcademic Press7586 63.HanSMallampalliRKThe role of surfactant in lung" exact="disease" post="and host defense against pulmonary infectionsAnn Am Thorac Soc201512576577410.1513/AnnalsATS.201411-507FR25742123"/>
 <result pre="role of surfactant in lung disease and host defense against" exact="pulmonary" post="infectionsAnn Am Thorac Soc201512576577410.1513/AnnalsATS.201411-507FR25742123 64.PlomerMde ZeeuwJMore than expectorant: new"/>
 <result pre="Medizin2017159Suppl 5223310.1007/s15006-017-9805-028643291 65.GaoXHuangYHanYBaiC-XWangGThe protective effects of Ambroxol in Pseudomonas aeruginosa-induced" exact="pneumonia" post="in ratsArch Med Sci20117340541310.5114/aoms.2011.2340322312374 66.Boehringer Ingelheim Limited (2016) Summary"/>
 <result pre="in Pseudomonas aeruginosa-induced pneumonia in ratsArch Med Sci20117340541310.5114/aoms.2011.2340322312374 66.Boehringer Ingelheim" exact="Limited" post="(2016) Summary of bisolvon product characteristics. https://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_PA0007-025-002_29042016142022.pdf. Accessed 20"/>
 <result pre="68.LaporteMNaesensLAirway proteases: an emerging drug target for influenza and other" exact="respiratory" post="virus infectionsCurr Opin Virol201724162410.1016/j.coviro.2017.03.01828414992 69.Waldrop T, Alsup D, McLaughlin"/>
 <result pre="71.KeyaertsELiSVijgenLRysmanEVerbeeckJVan RanstMet al.Antiviral activity of chloroquine against human coronavirus OC43" exact="infection" post="in newborn miceAntimicrob Agents Chemother20095383416342110.1128/aac.01509-0819506054 72.TanYWYamWKSunJChuJJHAn evaluation of chloroquine"/>
 <result pre="Res201814914314910.1016/j.antiviral.2017.11.01729175128 73.YanYZouZSunYLiXXuK-FWeiYet al.Anti-malaria drug chloroquine is highly effective in treating" exact="avian influenza" post="A H5N1 virus infection in an animal modelCell Res201323230030210.1038/cr.2012.16523208422"/>
 <result pre="chloroquine is highly effective in treating avian influenza A H5N1" exact="virus infection" post="in an animal modelCell Res201323230030210.1038/cr.2012.16523208422 74.PatonNILeeLXuYOoiEECheungYBArchuletaSet al.Chloroquine for influenza"/>
 <result pre="is highly effective in treating avian influenza A H5N1 virus" exact="infection" post="in an animal modelCell Res201323230030210.1038/cr.2012.16523208422 74.PatonNILeeLXuYOoiEECheungYBArchuletaSet al.Chloroquine for influenza"/>
 <result pre="fÃ¼r die gesamte Virusforschung19723619310410.1007/BF012502994335025 76.KeyaertsEVijgenLMaesPNeytsJVan RanstMIn vitro inhibition of severe" exact="acute" post="respiratory syndrome coronavirus by chloroquineBiochem Biophys Res Commun2004323126426810.1016/j.bbrc.2004.08.08515351731 77.InglotADComparison"/>
 <result pre="die gesamte Virusforschung19723619310410.1007/BF012502994335025 76.KeyaertsEVijgenLMaesPNeytsJVan RanstMIn vitro inhibition of severe acute" exact="respiratory" post="syndrome coronavirus by chloroquineBiochem Biophys Res Commun2004323126426810.1016/j.bbrc.2004.08.08515351731 77.InglotADComparison of"/>
 <result pre="gesamte Virusforschung19723619310410.1007/BF012502994335025 76.KeyaertsEVijgenLMaesPNeytsJVan RanstMIn vitro inhibition of severe acute respiratory" exact="syndrome" post="coronavirus by chloroquineBiochem Biophys Res Commun2004323126426810.1016/j.bbrc.2004.08.08515351731 77.InglotADComparison of the"/>
 <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis202010.1093/cid/ciaa23732161968 79.GoodMIShaderRILethality and"/>
 <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis202010.1093/cid/ciaa23732161968 79.GoodMIShaderRILethality and behavioral"/>
 <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2)Clin Infect Dis202010.1093/cid/ciaa23732161968 79.GoodMIShaderRILethality and behavioral side"/>
</results>
